AnBogen Therapeutics
Tracked across 4 events · 24 articles · First seen Jan 17, 2026 · Last active Jul 01, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: AnBogen Therapeutics announced two key research abstracts for its lead compound, Imofinostat (ABT-301), demonstrating its potential in enhancing immunotherapy for colorectal cancer and overcoming chemotherapy resistance in pancreatic cancer. The company is also advancing a Phase 1/2 clinical trial and plans for an Emerging Stock Market listing.
Apr 13, 2026 · 6 articles
Business
Impact: AnBogen Therapeutics engaged two consulting firms to advance its lead candidate, PT-00114, into Phase 2 clinical studies, which is expected to strengthen its operational processes and regulatory strategy.
May 19, 2026 · 6 articles
Business
Impact: AnBogen Therapeutics granted inducement awards to three new employees, consisting of stock options and restricted stock units, as a material inducement for their employment. This action aims to attract and retain talent, which is generally positive for the company's long-term prospects.
Jun 16, 2026 · 6 articles
100
AnBogen Therapeutics granted inducement awardsProtagonist Therapeutics...
ERGEN INTELLIGENCE
Track AnBogen Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard